Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IDRCB 2019 A01902-55 | Other Identifier | French National Health Agency |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Slb Pharma | OTHER |
| France Oxygène | UNKNOWN |
| MBar | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Background : Long-term home non-invasive ventilation (NIV) can be proposed as treatment for acute respiratory failure with severe alveolar hypoventilation. The aim of NIV is to correct both daytime and night-time hypoventilation and associated symptoms and to provide the patient with adequate night-time oxygen saturation. The benefits of long-term NIV in the management of chronic obstructive pulmonary disease (COPD) patients in a stable state remain controversial. This highlights the importance of identifying the predictive factors for good compliance to the NIV, defined as a use of more than 4 hours per day.
Aim of the study: The main objective is this observational study is to monitor the home NIV compliance over a period of 1 year under real conditions of treatment in patients with COPD newly initiated onto NIV (with telemonitoring or not) in order to specify the predictive criteria for good compliance. The secondary objectives are to assess the evolution of functional respiratory data, NIV parameters and changes in prescription, occurrence of acute exacerbations of COPD, hospitalizations and death, patient outcomes (quality of life and acceptability of NIV).
Study design: a cohort of 120 patients with COPD newly initiated onto home-NIV (with telemonitoring or not), either in a stable state or following an acute exacerbation will be enrolled in the study and follow-up over 1 year. Data will be collected by lung specialists and home health care provider teams at 1-month post-initiation of NIV, 6 months and 1 year. The study is conduct in France.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of the global compliance of the home-NIV over 1 year | For each patient, the total number of hours of NIV use divided by the number of days over the period of observation will be calculated. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Evolution of the mean duration of NIV use per day | The mean number of hours of NIV use per day will be calculated by period of 30 consecutive days at different times over the year of home NIV introduction. At each time, the proportion of patients with NIV use ≥ 4 hours per day will be calculated. | month 1, month 6, month 12 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Cohort of COPD patients who initiate long-term home-NIV.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gilles Jébrak, MD | Bichat Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pays d'Aix hospital | Aix-en-Provence | 13616 | France | |||
| Cannes hospital |
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D010349 | Patient Compliance |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
| Impact of the home-NIV on the medical condition of COPD patients |
The number of hospitalizations, COPD exacerbations, deaths will be monitored over 1 year. |
| 1 year |
| Impact of the home-NIV on the dyspnea | The respiratory function will be evaluated with the score of dyspnea assessed using the Modified Medical Research Council (mMRC) scale. The score ranges from 0 to 4 points; higher scores mean a high dyspnea. | At inclusion, month 6, month 12 |
| Impact of the home-NIV on the respiratory function | The pulmonologist will assess the evolution of respiratory function according to good medical practice with the pulmonary functional tests and blood gas analysis, and judge if the prescribed home-NIV treatment is sufficient to normalize the respiratory function or if the treatment must be modified. | At inclusion, month 6, month 12 |
| Impact of the home-NIV on the health related quality of life of COPD patients | the quality of life will be assessed using the COPD-specific health related quality of life questionnaire named VQ11. The questionnaire VQ11 comprises 11 items distributed across three components (functional: 3 items, psychological: 4 items, social: 4 items). The global score ranges from 11 to 55 points; higher scores mean a better quality of life. | At inclusion, month 6 |
| Assessment of home-NIV by patients | The home-NIV treatment will be assessed by patients using the S3-NIV questionnaire (this short questionnaire comprises 11 items distributed across three NIV-related components : respiratory Symptoms, Sleep quality and NIV-related Side effects. The global score varies between 0 to 10 points; higher scores mean a better outcome. | month 6 |
| Cannes |
| 06414 |
| France |
| Henri-Mondor hospital (APHP) | Créteil | 94010 | France |
| Institut Médical de Sologne Les Pins | Lamotte-Beuvron | 41600 | France |
| Le Havre Jacques Monod hospital | Montivilliers | 76290 | France |
| Pitié Salpétrière hospital (APHP) | Paris | 75013 | France |
| Bichat hospital | Paris | 75877 | France |
| Saint-Nazaire hospital | Saint-Nazaire | 44600 | France |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |